ω-Agatoxin IVA TFA: Benchmark P/Q-Type (Cav2.1) Calcium Channel Blocker

Executive Summary: ω-Agatoxin IVA TFA is a spider venom-derived peptide with nanomolar potency for P/Q-type (Cav2.1) calcium channels, exhibiting IC₅₀ values of 1–2 nM for P-type and up to 270.5±1.1 nM for Q-type channels with the NP motif (Cell Res, 2024). It shows minimal effects on N-type channels at 1 μM and no activity on L- or T-type channels. The compound inhibits presynaptic neurotransmitter release, mediates anticonvulsant and neuroprotective effects in epilepsy models, and provides a reproducible tool for neuronal calcium current and synaptic transmission assays (APExBIO C8722). Application protocols are optimized for both in vitro (100 nM–1 μM) and in vivo (0.01–1 nM) research. Storage and handling require cold, inert, and protected conditions for maximal activity.

Biological Rationale

Voltage-gated calcium channels (Cav) are essential for calcium influx triggered by membrane depolarization [Cell Res 2024]. The Cav2.1 (P/Q-type) channel, encoded by CACNA1A, is highly expressed in neurons and neuroendocrine cells. It mediates neurotransmitter release (e.g., glutamate, GABA) and regulates synaptic plasticity and neuronal excitability. Disruption of Cav2.1 function is implicated in several neurological disorders, including epilepsy and migraine. P-type channels are found in cerebellar Purkinje cells, while Q-type channels are present in cerebellar granule cells; both subtypes have distinct inactivation kinetics and sensitivities to peptide toxins [Fig. S1a]. Specific blockade of Cav2.1 is crucial for dissecting calcium channel–dependent signaling in neurophysiology and disease models.

Mechanism of Action of ω-Agatoxin IVA TFA

ω-Agatoxin IVA TFA is a 48-residue peptide toxin isolated from the venom of Agelenopsis aperta (funnel-web spider), provided here in trifluoroacetate salt form. It selectively binds to the extracellular periphery of the voltage-sensing domain IV (VSDIV) of Cav2.1 channels, thereby inhibiting the opening of the channel pore [Fig. 1a]. The toxin exhibits highest affinity (IC₅₀ = 1–2 nM) for P-type Cav2.1 channels lacking the NP motif and reduced potency (IC₅₀ up to 270.5±1.1 nM) for Q-type channels containing the NP motif, as demonstrated by electrophysiological and cryo-EM studies. At 1 μM, ω-Agatoxin IVA TFA only partially inhibits N-type (Cav2.2) channels and exerts no effect on L-type (Cav1.x) or T-type (Cav3.x) channels. This selectivity is driven by key structural differences in the extracellular loops of Cav2.1 subtypes, which determine toxin binding and channel blockage. By blocking Cav2.1, the toxin suppresses presynaptic calcium influx, leading to inhibition of neurotransmitter (glutamate, GABA) release and modulation of synaptic transmission. This mechanism underlies its anticonvulsant and neuroprotective actions in animal models.

Evidence & Benchmarks

• ω-Agatoxin IVA TFA blocks P-type Cav2.1 channels with nanomolar potency (IC₅₀ = 1–2 nM), as validated by patch-clamp electrophysiology and structural studies (Cell Res 2024).
• Q-type Cav2.1 channels with the NP motif display significantly reduced sensitivity (IC₅₀ = 270.5±1.1 nM), confirming the role of alternative splicing in toxin affinity (Fig. S6/Table S1).
• At 1 μM, ω-Agatoxin IVA TFA weakly and partially inhibits N-type (Cav2.2) calcium currents, with no effect on L-type or T-type channels, supporting its selectivity profile (Text/Table S1).
• In acute epilepsy animal models, intracerebroventricular injection of 0.01–1 nM prolongs seizure latency and increases BDNF expression without impairing motor coordination (APExBIO).
• Reductions in cleaved caspase-3 expression and intracerebral apoptosis are observed after ω-Agatoxin IVA TFA administration in kindling epilepsy models, indicating neuroprotection (APExBIO).

This article clarifies and extends the mechanistic detail found in "ω-Agatoxin IVA TFA: Precision Cav2.1 Blockade in Neurosci...", by incorporating the latest cryo-EM structural findings and explicit dose-response benchmarks.

For a broader translational perspective, see "ω-Agatoxin IVA TFA: Precision Disruption of Cav2.1 Signal...", which this article updates with new data on NP motif-dependent selectivity.

Applications, Limits & Misconceptions

ω-Agatoxin IVA TFA is primarily used for:

• In vitro neuronal calcium current recording (100 nM–1 μM).
• Synaptic transmission studies in brain slices or cultured neurons.
• Acute and kindling epilepsy animal models (0.01–1 nM, i.c.v. or 0.1–0.5 nM, i.p.).
• Neuroprotection assays assessing apoptosis markers and BDNF expression.
• Dissecting P/Q-type channel contributions to neurotransmitter release and synaptic integration.

Its specificity, potency, and reproducibility make it a gold-standard reagent for Cav2.1 inhibition. For a practical, scenario-driven guide to experimental use, see "Solving Lab Challenges with ω-Agatoxin IVA TFA (SKU C8722...)"; here, we further emphasize mechanistic context and benchmark parameters.

Common Pitfalls or Misconceptions

• Not a pan-calcium channel blocker: Ineffective against L-type (Cav1.x) and T-type (Cav3.x) channels under standard assay conditions [Table S1].
• Limited N-type activity: Only partial inhibition at high micromolar concentrations; not recommended for exclusive Cav2.2 studies.
• NP motif reduces efficacy: Q-type channels with NP insertion show much lower sensitivity, requiring higher concentrations for effect.
• Solution stability: Peptide solutions are not stable for long-term storage; fresh preparation is recommended for reproducibility.
• Storage conditions: Degradation occurs if not stored at –20°C under nitrogen, protected from light and moisture.

Workflow Integration & Parameters

For in vitro use, ω-Agatoxin IVA TFA is typically applied at 100 nM–1 μM in extracellular solution during whole-cell patch-clamp or synaptic transmission recordings. For animal models, intracerebroventricular (i.c.v.) doses of 0.01–1 nM and intraperitoneal (i.p.) doses of 0.1–0.5 nM have been validated for seizure latency and neuroprotection endpoints. The molecular weight is 5316.27 Da, and the chemical formula is C₂₁₇H₃₆₀N₆₈O₆₀S₁₀·C₂HF₃O₂. Solutions should be prepared in sterile water or buffer and used immediately; avoid repeated freeze-thaw cycles. The product (APExBIO C8722) ships under blue ice or dry ice depending on the molecule class. For detailed guidance on protocol integration and troubleshooting, refer to "ω-Agatoxin IVA TFA: Benchmark P/Q-Type Calcium Channel Bl...", which this article complements with updated selectivity data and in vivo benchmarks.

Conclusion & Outlook

ω-Agatoxin IVA TFA (APExBIO C8722) is a definitive research reagent for specific Cav2.1 channel inhibition. Its nanomolar potency, structural selectivity, and validated neuroprotective effects in epilepsy models make it indispensable for advanced neurophysiology and translational research. As structural and functional data expand, ω-Agatoxin IVA TFA will continue to serve as a reference compound for dissecting calcium channel–mediated signaling, informing both mechanistic understanding and therapeutic development.